There are numerous data from Phase I/II trials support the use of Palbociclib (CDK 4/6 inhibitor),7–10 Gedatolisib (PI3K/mTOR dual inhibitors),11,12 and PD0325901 (selective MEK1/2 inhibitor)13–15 as single agents in various types of cancers. This evidence concerns the gene MAP2K1 and cancer.